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Abstract
OBJECTIVES—Mental health and substance abuse (MH/SA) comorbidities are the most oft-
cited reasons for deferral from peginterferon (PegIFN) therapy for chronic hepatitis C virus
(HCV). We sought to determine whether an integrated care intervention (INT) for patients
deferred from PegIFN owing to MH/SA could improve subsequent treatment eligibility rates.
METHODS—In this randomized controlled trial, 101 HCV patients who were evaluated at two
hepatology centers and deferred from antiviral therapy owing to MH/SA were enrolled.
Participants were randomized to an INT (N = 50) or standard of care (SC; N = 51). The INT group
received counseling and case management for up to 9 months. All participants underwent 3-, 6-,
and 9-month clinical follow-up visits, where hepatologists, masked to group, re-evaluated patients
for treatment eligibility. Standardized mood and alcohol use instruments were administered to all
participants to aid clinicians in treatment decisions.
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RESULTS—Of 101 participants, the mean age was 48 years and 50% were men, 61% Caucasian,
and 77% genotype 1. Patients were initially deferred owing to psychiatric issues (35%), alcohol
abuse (31%), drug abuse (9%), or more than one of these reasons (26%). In an intent-to-treat
analysis, 42% (21/50) of INT participants became eligible for therapy compared to 18% (9/51) of
SC participants (P = 0.009, relative risk (RR) = 2.38, 95% confidence interval (CI) (1.21, 4.68)).
When baseline predictors significant at P < 0.10 in univariate models were entered into
multivariate models adjusted for treatment group, only baseline depression remained significant (P
= 0.05, RR = 0.98, 95% CI (0.96, 1.00)). With the exception of a model adjusted for genotype,
treatment group remained significant in all models.
CONCLUSIONS—This trial suggests that INTs can increase eligibility for HCV treatment and
expand treatment to the underserved population with MH/SA comorbidities.
INTRODUCTION
Many patients diagnosed with chronic hepatitis C viral (HCV) infection are ineligible for
peginterferon (PegIFN) and ribavirin treatment owing to one or more comorbid conditions
that may interfere with its safe administration. This phenomenon occurs consistently across
a variety of treatment settings (1–4). Although some patients are deferred owing to advanced
liver disease or patient preference, the majority of patients are ineligible owing to mental
health or substance abuse (MH/SA) issues (1,4–6). Moreover, very few patients who are
initially deferred from treatment owing to MH/SA ever proceed to antiviral treatment in the
future (1,2,6). Although most MH/SA problems are manageable, a large number of these
patients are left untreated for reasons that may include ongoing instability of MH/SA
conditions, lack of concurrent MH/SA care, or concerns regarding non-adherence,
neuropsychiatric syndromes, and SA worsening during PegIFN treatment. Some of these
concerns, however, have not withstood empirical scrutiny and are no longer viewed as
justifiable reasons to withhold antiviral therapy (7–10). Studies have demonstrated that
patients with concurrent MH/SA issues can safely and successfully complete PegIFN
treatment when treatment is delivered in the context of a multidisciplinary team in which
MH/SA services are integrated with medical care (10–14). Despite this evidence, and the
2002 and 2009 treatment guidelines, patients with MH/SA issues continue to have difficulty
accessing treatment (1,4,15,16). A lack of integrated care models that provide MH/SA
management may be one of the structural barriers responsible for the sluggish uptake of
these guidelines (14,17,18).
The barriers to treating HCV in patients with MH/SA comorbidities are of concern from a
public, as well as an individual, health perspective. HCV is highly prevalent in current drug
users and in patients with mental illness, much more so than in the general population (19–
22). It has become more apparent that comprehensive team approaches will be needed to
overcome barriers and increase successful treatment of the multitude of individuals with
MH/SA who await treatment for this potentially life-threatening disease (23–28). Integrating
MH/SA into standard medical care may augment the treatment effectiveness of antiviral
therapy and have a greater impact on public health outcomes.
Comprehensive team approaches are often referred to as “integrated models of care,” and
have become a relatively standard model for other chronic illnesses, such as HIV, diabetes
mellitus, and cancer (12,14,28,29). Integrated models of care are defined as any strategy or
intervention “intended to improve the coordination of care and communication among
caregivers, streamline protocols for movement across the care system, co-locate services, or
deploy fully integrated service teams” ((28) pg. S228). Therefore, integrated care models
can encompass everything from improving communication and collaboration between MH/
SA specialists and HCV treatment providers to a fully integrated multidisciplinary team
approach, in which hepatology and MH/SA specialists coexist in the same clinic (14,25,26).
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A few examples of innovative integrated care models for HCV are described in the
literature, and provide support for the favorable impact of such models on all aspects of
disease management (12,14,29–31). With the exception of one recent study (31), no
randomized controlled trials (RCTs) have compared different models of care to standard
care, and no study has explored the impact of such models on increasing access to care and
improving treatment eligibility rates.
Objectives and hypotheses
The primary objective of this study was to determine whether a 9-month integrated care
intervention (INT) could increase the proportion of HCV patients with MH/SA
comorbidities who are deemed eligible for PegIFN treatment compared to patients who
receive standard medical care. We hypothesized that a significantly higher proportion of
patients randomized to the intervention would become eligible for PegIFN treatment at the
end of a 9-month trial compared to patients who receive standard care.
A secondary objective of this study was to elucidate other baseline predictors of treatment
eligibility. We hypothesized that certain baseline characteristics would contribute to
predicting eligibility, over and above the impact of treatment condition.
METHODS
Overview of study design
This study was a multi-site, prospective, randomized, single-blinded, controlled intervention
trial to evaluate the impact of an INT on treatment eligibility rates among patients deferred
from antiviral therapy owing to MH/SA comorbidities. Participants (n = 101) were randomly
assigned to standard of care (SC) or an INT, which included SC procedures plus an
intervention. Participants were scheduled for follow-up clinic appointments at 3, 6, and 9
months, at which time a hepatology clinician, masked to group assignment, re-evaluated
patients’ eligibility for PegIFN treatment. The INT group participated in monthly phone and
in-person intervention sessions with the hepatology psychologist for up to 9 months.
Sessions were individually tailored for each patient, and used case management and
motivational-enhancement techniques (METs). The primary outcome of the study was the
proportion of participants in each group who were deemed eligible by a hepatology clinician
during the 9-month time period.
Patient population and setting
Participants were recruited from two outpatient specialty hepatology practices, one located
at a large academic medical center and the other at an affiliated community medical center.
Recruitment occurred between 2006 and 2009, and the study was completed in 2010. The
majority of patients were recruited from a clinic dedicated to HCV study and supervised by
a hepatologist with 21 years of experience (M.W.F.). Patients were also referred to the study
for screening from seven other gastrointestinal clinicians, most of whom were other
hepatology attendings with 12 years (range 5–15) of experience, on average, in HCV
management. The study was approved by the Institutional Review Boards of both
institutions. All participants provided written informed consent.
During initial clinic visits, all patients with HCV were routinely evaluated by a hepatology
clinician for potential candidacy for PegIFN treatment. Patients who were deferred by the
clinician from proceeding to PegIFN treatment owing to MH/SA comorbidities were
referred and screened for study participation. Inclusion criteria included: new referral for
HCV; deferred from treatment owing to MH or SA issues; a confirmed diagnosis of HCV;
expressed interest in treatment; and medically cleared by the hepatologist to have no other
Evon et al. Page 3













contraindications for PegIFN treatment. Exclusion criteria included: diagnosis of psychotic
disorders; living in a psychiatric residential facility; suicide attempt in the past 5 years;
active intravenous drug use; cognitively impaired owing to brain disease or injury; advanced
liver disease or other medical comorbidity that excluded them from PegIFN treatment, not
interested in pursuing treatment; homelessness; no telephone access; and non-English
speaking.
Recruitment and randomization procedures
Hepatology clinicians notified research coordinators of patients deferred from treatment and
eligible for the trial. The coordinator screened and consented patients, and then randomly
assigned them to INT or SC following a simple randomization procedure using a computer-
generated list of random numbers. The allocation sequence was created by a researcher with
no involvement in the trial, and the sequence concealed from study personnel until
assignment occurred. When a coordinator was unavailable to recruit a patient who had
expressed interest in the study, three phone calls were made to reach the patient. Patients
who gave verbal consent to participate over the phone were then randomized and scheduled
to attend a baseline 2 visit, at which time written consent was obtained.
SC procedures
Our comparison condition was an enhanced version of standard medical care in a hepatology
clinic. Participants in both the SC and INT groups received the following standard
procedures:
Baseline 1—During the first clinical visit, hepatology clinicians evaluated patients’
eligibility for PegIFN treatment using the 2002 published recommendations on treatment
eligibility (32). If judged to be a poor candidate for treatment owing to MH/SA problems,
the clinician counseled the patient on the rationale for deferral (e.g., significant depression,
active alcohol abuse), and provided recommendations to achieve treatment eligibility (e.g.,
treatment for depression, cessation and treatment for alcohol abuse). Initial visits with the
hepatologist may also have covered the following topics: significance of genotype; biopsy
findings; review of PegIFN treatment regimen; response rates; psychiatric and constitutional
side effects of PegIFN, with emphasis on psychiatric symptoms if psychiatric history
present; avoidance of alcohol and illicit substances, which are known to advance cirrhosis;
and screening for complications of liver disease. After this face-to-face discussion, the
clinician then gave the patient specific written treatment recommendations, which if
followed, should enhance his/her chances of becoming eligible for treatment through
addressing the MH/SA concerns. These five Physician Treatment Recommendation
handouts were developed a priori by members of the HCV treatment team to address minor
and major MH concerns, minor and major alcohol abuse, and SA. See Supplementary
Document 1 online for an example of a recommendation form addressing major alcohol
consumption. In addition to receiving one or more handouts, participants received a book
about hepatitis C, and a follow-up appointment in 3 months. All participants completed four
baseline self-report instruments, and appointments were scheduled to attend the baseline 2
research visit within 3 weeks.
Baseline 2—All participants were scheduled to undergo a Structured Clinical Interview for
the DSM-IV (SCID) to determine psychiatric diagnosis. Participants in the INT condition
were evaluated by the hepatology psychologist, and SC participants were evaluated by a
research coordinator who received 30 + h of SCID training. After conducting a SCID, study
personnel reviewed the Physician Treatment Recommendation handouts that each
participant had received previously. To prevent therapy drift, coordinators were not allowed
to discuss strategies or provide assistance in adhering to these treatment recommendations
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with the SC participants. The interventionist conducted the first intervention session after
completing the SCID with each INT participant.
Follow-up clinic visits—All participants were scheduled for 3-, 6-, and 9-month clinic
visits for re-evaluation of eligibility for PegIFN therapy with a hepatology clinician masked
to group assignment. All participants were mailed an appointment slip and received an
automated telephone reminder before the scheduled visit. Upon arrival to the clinic,
participants completed three self-report instruments to assess alcohol use, depression, and
anxiety. In addition, study personnel completed a Patient Outcome Form (see
Supplementary Document 2 online) at each visit by querying participants about actions
taken to address the Physician Treatment Recommendations since the last visit. The purpose
of this brief screening form was to provide standardized data to the clinician to facilitate
consistent and well-informed decisions regarding treatment eligibility. The Patient Outcome
Form was reviewed with the hepatology clinician before their clinical encounter with the
patient. During the follow-up visit with the patient, the hepatology clinician inquired into the
issues that previously precluded treatment, and to what extent the patient had made progress
on following the treatment recommendations. After reviewing the data and re-evaluating the
patient, the clinician made a decision about treatment eligibility. If deferred again, the
participant continued in the trial and was re-evaluated at 6 and/or 9 months.
INT condition
The overarching aim of the intervention was to assist patients in adhering to the Physician
Treatment Recommendations, which if followed, would ultimately improve their candidacy
for PegIFN therapy. In addition to the standard procedures described above, the INT
participants engaged in up to 9 months of sessions with the hepatology psychologist to assist
them in addressing the Physician Treatment Recommendations regarding MH/SA concerns.
The initial intervention session was conducted after the SCID at baseline 2, and then
participants were scheduled for monthly intervention sessions delivered by telephone (at
months 1, 2, 4, 5, 7, and 8) and in person (after clinic visit at months 3 and 6). In addition,
INT participants received two reminder phone calls by the coordinator before each
scheduled phone or clinic visit. For phone sessions, the psychologist made two attempts to
contact the patient, and if unreachable, waited until the next scheduled phone call/visit to
make contact.
The INT for this trial was developed taking into consideration patient characteristics of those
evaluated at our clinical sites. The majority of the intervention was delivered over the
telephone to reduce travel and financial burden. Whenever possible (in the majority of
cases), the interventionist linked INT participants to local MH/SA programs to reduce travel
burden and help patients establish contact with local resources for long-term management of
MH/SA disorders. In cases where patients were unable or unwilling to see a MH/SA
provider locally, the interventionist would provide monthly counsel to help participants
follow the Physician Treatment Recommendations. When individuals were unable or
unwilling to obtain MH/SA services, they were encouraged to discuss pharmacological
treatment with their internist, consider 12-step programs, or were aided in harm reduction
efforts during monthly phone sessions.
The intervention sessions were based on three fields of research: (1) the Stages of Change
model; (2) case management strategies; and (3) motivational enhancement techniques
(METs). The interventionist was guided by the Stages of Change model, which posits that
individuals move through a sequence of five stages as they contemplate, initiate, and
maintain new behaviors (33,34). Theoretically, deferred patients would be in various stages
of readiness to address their problems, but we presumed that case management strategies
Evon et al. Page 5













and enhancing patient motivation would be critical for most (33,34). Thus, the
interventionist determined stage of readiness and employed counseling strategies that
matched that particular stage (35). For patients who were motivated to address their
problems, case management strategies were primarily employed, such as identifying
appropriate local MH/SA services and assisting with referral and follow-up with MH/SA
providers (36–38). Finally, we presumed many patients would be ambivalent about changing
behaviors, thus a counseling style known as “METs” was most appropriate and employed
with these patients. Broadly speaking, METs are clinical strategies designed to enhance
motivation to make positive behavioral changes and engage ambivalent patients in a dialog
that may eventually lead to making positive choices (35,39). Although originally developed
for problem drinkers, METs have since been successfully applied in many other patient
populations and clinical settings (39).
Masking procedures
It was critical to mask hepatology clinicians to group assignment because they were
responsible for making the final determination regarding treatment eligibility, the primary
outcome of the study. The interactions between study personnel and clinicians when patients
presented in clinic for re-evaluation posed the greatest threat to unblinding; thus, several
precautions were established to minimize this threat. The importance of blinding procedures
was reviewed frequently with hepatology clinicians and participants at each follow-up visit.
Study personnel were vigilant to reviewing the Patient Outcome Form with the hepatology
clinician in an objective and unbiased manner, and were not allowed to offer opinions
regarding readiness for treatment. Discussions between study personnel and participants
were held in private exam rooms, and all participants were asked not to divulge any
information that could identify group assignment. When a clinician requested further
clarification about the information provided by the patient, he/she was encouraged to
address further inquiries with the patient. At no time during the study did a clinician or
patient report comprising the masking requirements.
Measures
Baseline demographics—At baseline 1, participants completed a demographic
characteristics form. Reasons for deferral and genotype were collected from medical chart
review.
Depression, anxiety, and alcohol use—At baseline 1 and 3-, 6-, and 9-month follow-
up visits, all participants completed depression, anxiety, and alcohol use instruments. The
Beck Depression Inventory-II assessed depressive symptoms (40). The Spielberger Trait
Anxiety Inventory assessed trait anxiety (41). The Alcohol Use Disorders Identification Test
assessed frequency and severity of alcohol use (42). The baseline measures were collected to
serve as covariates in regression models, and clinicians were not privy to these data. Data
collected during follow-up visits were included on the Patient Outcome Form and used by
the clinicians to make decisions regarding treatment eligibility.
Readiness for change—The University of Rhode Island Change Assessment Scale was
used to assess individuals’ readiness to address their MH or SA problem (33). All
participants completed a University of Rhode Island Change Assessment Scale at baseline 1
and these data served as covariates in regression models. The University of Rhode Island
Change Assessment Scale was completed only by INT participants at follow-up visits to
guide the intervention.
Psychiatric diagnosis—At baseline 2, the SCID modules to diagnose mood, anxiety,
alcohol, and substance use disorders were used to make psychiatric diagnoses (43). SCID
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data were collected to use as covariates in models, and for clinical purposes to make
accurate diagnoses of deferral reasons and guide interventions with INT participants.
Primary outcome—The primary end point for the study was the proportion of participants
in INT and SC who were deemed eligible for PegIFN treatment by masked hepatology
clinicians at the end of a 9-month time period. Binary data (eligible vs. ineligible) were
collected at 3-, 6-, and 9-month follow-up clinic visits. Clinicians had the following data
available to them to inform their treatment decision: (i) self-report questionnaires assessing
depression, anxiety, and alcohol abuse; (ii) Patient Outcome Form; (iii) physical exam/
clinical evaluation; (iv) laboratory data; and (v) urine toxicology screens (when available
and appropriate).
Data analysis—During study design, estimating that after 9 months of intervention, 55%
of INT participants would be eligible for PegIFN therapy compared to 25% of SC
participants, we had 83% power at P = 0.05 to detect statistical significance between
treatment groups. For the primary outcome analyses, an intent-to-treat analysis was
conducted using data from all 101 randomized participants. The association between
treatment group and the primary outcome (final eligibility at 9 months) was assessed with a
two-sided Fisher’s exact test. To determine if any group differences existed, baseline
demographic, depression, anxiety, readiness for change, reasons for deferral, and provider
were compared by group condition. Continuous and categorical variables were compared via
t -test and Fisher’s exact test, respectively. To determine if any baseline characteristics were
predictive of PegIFN treatment eligibility after accounting for treatment condition, we ran
logistic regression models with a dichotomous response and a log link to ascertain relative
risk. First, each potential covariate was entered into a model by itself and the ones that
resulted in P< 0.10 were noted. Each of these covariates was then added singly to a model
containing treatment condition. If any covariate had a P< 0.05, it was included in a model
with treatment condition, and then the process was repeated again, with the other variables,
until no new covariates were significant at P< 0.05.
RESULTS
Patient characteristics
Participant flowchart is depicted in Figure 1 and baseline characteristics are described in
Table 1. A total of 136 patients were deferred from PegIFN treatment and referred for study
screening. Of these, 35 patients were excluded. Patients who were randomized in person (n
= 81) vs. telephone (n = 20) did not differ significantly by treatment group or final treatment
eligibility. The majority of patients (79%) were evaluated by the same hepatology attending,
whereas the remaining patients were evaluated by other hepatology clinicians. A Fisher’s
exact test determined that there was no statistically significant difference between treatment
conditions by provider (P = 0.62). A total of 101 patients were randomized to treatment
condition.
With regard to deferral reasons of the 101 study participants at baseline, 35% were deferred
by clinicians for MH issues only, 31% were deferred for alcohol issues only, 9% were
deferred for substance use issues only, and 26% were deferred for two or more reasons. Out
of 101 participants, 62 attended the SCID assessment at baseline 2, and of these, 68% were
diagnosed with lifetime or current unipolar, bipolar depression, or adjustment disorder; 39%
with anxiety disorders; 66% with substance use disorders; and 82% with alcohol use
disorders. Most patients had more than one lifetime or current MH/SA diagnosis.
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Effect of INT on eligibility for PegIFN treatment
In an intent-to-treat analysis, patients who participated in INT were more likely to become
eligible for PegIFN treatment by the end of the 9-month trial compared to participants in SC
(42% vs. 18%, P = 0.009) (Figure 2). Participants in the intervention condition were almost
2.4 times more likely to become eligible by 9 months (95% confidence intervals = 1.2, 4.7).
Eight patients became eligible (6 INT, 2 SC) at the 3-month follow-up visit, 14 patients (9
INT, 5 SC) at 6-month visit, and 8 patients (6 INT, 2 SC) at 9-month visit.
Patient characteristics associated with eligibility for PegIFN treatment in multivariate
models
The following baseline patient characteristics had a P< 0.10 in bivariate tests with treatment
eligibility: race; income level; genotype; depression; anxiety; and readiness for change.
Baseline depression and anxiety were highly correlated (r = 0.90); therefore, only depression
was considered for inclusion in multivariate modeling. When each of these five variables
were added singly to a model that contained treatment condition, only baseline depression
remained significant at P< 0.05, although other variables approached significance (Table 2).
When the remaining four variables were then added singly to a model, which then contained
treatment condition and baseline depression, none remained significant at P< 0.05. Finally,
treatment condition remained statistically significant at P< 0.05 when other variables were
singly entered into the models, with the exception of a model that included genotype (P =
0.07; all data not shown).
Preliminary results on antiviral treatment uptake
Patients who were deemed eligible to proceed with antiviral therapy from an MH/SA
perspective are being followed in an observational study utilizing medical chart extraction.
These data demonstrate the following: Of the 30 patients (21 INT, 9 SC) who were deemed
eligible to proceed to antiviral therapy, 12/21 (57%) of INT participants and 7/9 (78%) of
SC participants have started treatment (P = 0.42). Of the 19 patients to start treatment, 18
(95%) have continued on treatment past week 4 (one patient discontinued at week 4 owing
to increased depression and irritability). Out of the 11 patients (2 = SC, 9 = INT) who have
yet to start treatment, chart extraction revealed the following reasons for treatment
postponement: medical issues requiring further attention (n = 5); awaiting triple therapy (n =
2); patient preference due to occupational or personal issue (n = 2); relapse to drugs/alcohol
(n = 2); and lost to follow-up (n = 2). Patients may have had more than one reason for non-
treatment. An overall comparison between the two groups indicated that 24% of the INT
group have started treatment at this time (12/50) compared to 14% (7/51) of the SC
condition (P = 0.21).
DISCUSSION
Despite an estimated 3.9 million individuals infected with hepatitis C in the United States,
only a small fraction have successfully undergone antiviral therapy (44–46). Barriers are
pervasive at multiple junctures in the process from HCV screening to successful completion
of antiviral treatment. First, significant barriers exist in proceeding from a positive screen for
HCV to being referred to a clinic that provides antiviral therapy (46–48). Barriers, such as
ongoing psychiatric and SA comorbidities, continue to exist after patients have gained entry
into HCV treatment centers (1). Finally, the difficult treatment regimen and adverse side
effects diminish treatment completion rates (49).
This study was an effort to overcome the most prevalent barriers at the second juncture in
this funneling-down process. This randomized clinical trial evaluated the impact of an INT
on eligibility for PegIFN therapy among HCV patients who were originally deferred from
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treatment owing to two highly prevalent barriers to treatment: MH and SA comorbidities.
We developed an intervention that was guided by the Stages of Change model, and
employed case management and motivational-enhancing counseling strategies, which were
delivered by the hepatology psychologist on a monthly basis by telephone and in person for
up to 9 months. All participants in the study received enhanced SC, which included
standardized screening instruments, written treatment recommendations addressing the
comorbidity that led to deferral from treatment at baseline, a book on hepatitis C, and
follow-up clinic visits at 3-month intervals for re-evaluation of treatment eligibility by
hepatologists. Patients who participated in the intervention were 2.4 times more likely to
overcome barriers and be deemed eligible for PegIFN treatment compared to patients who
received standard care. This study is the first investigation to demonstrate the efficacy of an
integrated care approach on HCV treatment eligibility rates in the context of a clinical trial
design.
In a previous retrospective analysis of treatment deferral rates at our hepatology clinic, only
16% of patients originally deferred from PegIFN treatment owing to MH/SA subsequently
became eligible for therapy in the future (1). As we designed the current trial to of er
enhanced SC procedures, we anticipated relatively higher eligibility rates (~25%) for
participants in the SC condition. However, this was not the case. Despite enhancement of
standard procedures, the eligibility rate for standard care participants was not significantly
higher than the results of the earlier study (18% vs. 16%). Thus, written treatment
recommendations, educational materials, and frequently scheduled follow-up visits, while
necessary, may be insuficient tactics for improving adherence to hepatologists’ treatment
recommendations. Clearly, additional interventions beyond these procedures will be needed
to assist patients in making requisite behavioral changes to improve treatment eligibility.
Integrated care models are becoming increasingly common for the management and
treatment of other conditions, such as HIV (27,28,50). With increased recognition of the
similarities between the HIV and HCV populations, as well as the medication regimens, a
similar paradigm shift in disease management of HCV may be warranted (25,28,51). The
VA system, with an infrastructure that lends itself well to integrated care models, has taken
the lead in spear-heading interdisciplinary management strategies to improve the care of
veterans with HCV and comorbid MH/SA (12,28). Several VA-based observational studies
have demonstrated that veterans with MH/SA comorbidities can access and successfully
complete PegIFN therapy when managed within an integrated care context (14,23,29,52,53).
In one study, a psychiatric clinical nurse specialist was co-located in the HCV clinic to
provide SA treatment and stabilize psychiatric symptoms, while preparing patients for
antiviral therapy (29). Patients were screened for MH/SA disorders and referred as needed to
the psychiatric clinical nurse specialist who provided case management, referrals,
counseling, and psychotropic medications. Similar to our study, treatment was individually
tailored to meet the needs of each patient. The results of their retrospective analysis were
very congruent with our findings: 47% of patients who were followed by the psychiatric
clinical nurse specialist became eligible for PegIFN therapy compared to 16% of patients
who did not participate in the integrated care. Although these findings were very
encouraging, they were limited by the retrospective, non-randomized, study design.
In this study, the intervention was designed to be individually tailored to address each
patient’s reason for deferral, motivation level, and availability of community resources.
Although the absence of a manualized intervention may be perceived as a limitation, it is
also a strength of the study as it allowed the interventionist to meet the unique needs of each
patient. Given the heterogeneity of deferral reasons (i.e., psychiatric, alcohol, illicit drugs,
dual diagnoses) and differing levels of patient motivation, it is imperative to match
counseling strategies to each patient and their motivational level (35,39). Another important
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factor to consider is the availability of MH/SA services in a patient’s local community,
which could be effected by health insurance status and rural vs. urban living.
This study employed standard operating procedures of clinical trial methodology and
represents a significant strength of the study. The RCT design allowed us to empirically test
for differences between the treatment conditions, something that previous investigations of
integrated care models in HCV have been unable to do. The use of valid and reliable
screening instruments increased the quality and consistency of hepatologists’ treatment
decisions. Standardized procedures (e.g., universal written treatment recommendations,
masking procedures, standard intervals between clinic visits) reduced the risk of bias, which
could have affected our primary outcome. These standardized procedures increase the
credibility of our findings and instill greater confidence that the group differences in
treatment eligibility were due to the intervention, and not other confounding variables.
Limitations of this study include the absence of treatment fidelity measures to assess the
quality of the intervention and the possibility of experimenter bias influencing the clinicians’
treatment eligibility decisions. The absence of audio-taping of intervention sessions
precludes conducting qualitative analyses to better understand why the intervention worked.
Despite tremendous effort to mask clinicians who were responsible for assessment of the
primary outcome, it is possible that investigator–clinician interactions during follow-up
visits could have influenced clinicians’ decisions. However, we were vigilant to this issue
from the start and instituted several procedures to minimize unblinding; at no time during
the study did any clinician or patient report violation of masking procedures. Similarly, it is
theoretically possible that the intervention simply coached patients to appear like appropriate
candidates, without actually changing their underlying MH/SA issues. We are currently
following patients in a clinical observational study to collect treatment uptake and outcome
data. Although this study is not complete, the preliminary data suggest that: (a) other non-
MH/SA issues (e.g., medical issues, awaiting triple therapy) may contribute to further
postponement of antiviral treatment, and (b) the majority of patients who start HCV
treatment appear to tolerate and persist on the medical regimen. These limited data on
treatment uptake and outcomes are based on very small numbers, and final conclusions
should be based on a complete data set and after the new antiviral regimens are
implemented.
This study can serve as a springboard for future investigations. Although this trial
demonstrates the efficacy of a multi-component intervention, subsequent analyses need to
elucidate individual components or active ingredients responsible for improvements in
eligibility rates. Inclusion of treatment fidelity measures, such as audio-taping, would allow
us to home in on active treatment ingredients. The cost-effectiveness of intervention delivery
needs to be examined. While this interventionist was a PhD-level clinical psychologist co-
located in the hepatology clinic, it is likely that others (e.g., nurses, social workers) could be
trained to deliver similar interventions in community-based clinics, where it may be less
feasible to staff a, MH/SA provider. Future studies should also determine the optimal length
of INTs, and if different strategies work best for psychiatric vs. SA populations. Finally,
investigations of novel intervention delivery methods, such as internet-based or texting
approaches (54), should also be explored. It is essential that investigators interested in
developing models to improve access to care do so within the unique infrastructure and
configuration of the clinical environment so that procedures are feasible and sustainable.
Although the development of models to fit the unique configurations of various treatment
settings poses challenges for replication and generalizability in the short run, it behooves us
to discover the most appropriate models of care befitting a variety of different HCV
treatment clinics, in the long run.
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Given that a majority of HCV patients have yet to receive antiviral treatment, in large part
due to MH/SA comorbidities, novel health service approaches, such as the one tested in this
trial, need to be developed to improve disease management. Reforming our current models
of care is of tremendous public health importance now, as we look forward to the next
generation of antiviral therapies. Clinicians should anticipate a re-emergence of patients
with MH/SA comorbidities who were previously deferred from treatment when the risk–
benefit ratio dissuaded many providers and patients from attempting treatment. Triple
therapy will alter the risk–benefit ratio and tip in favor of attempting treatment with a more
diverse group of patients such as those included in this study. The development of
innovative, cost-effective, and practical integrated care solutions is timely and urgently
needed to address the scope of this public health problem. The INT developed for this trial
may not generalize to all clinical settings, but will lay the groundwork for the exploration of
other health service models that have the potential to increase access to, and successful
treatment for a vast number of infected individuals who still await treatment.
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WHAT IS CURRENT KNOWLEDGE
✓ A majority of patients with chronic hepatitis C are deferred from antiviral therapy
owing to mental health and substance abuse comorbidities.
✓ Retrospective and prospective observational studies suggest that integrated or
multidisciplinary treatment models may increase the number of patients who become
eligible for, and successfully complete antiviral treatment.
WHAT IS NEW HERE
✓ This is the one of the first studies to test an integrated care model for chronic
hepatitis C patients using a clinical trial design.
✓ Novel health service approaches, such as integrated care intervention models, can
increase the eligibility for HCV treatment and expand treatment to the underserved
population with mental health and substance abuse comorbidities.
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Participant flowchart. Note: aIntervention participants received reminder phone calls before
every clinic visit (months 3, 6, and 9) and scheduled phone session (months 1, 2, 4, 5, 7, and
8). 1aAttended this clinic visit. 1bAttended and deemed eligible for treatment at this visit.
Numbers not cumulative. 2Did not attend this clinic visit, but continued participation in
study. Numbers not cumulative. 3Withdrawn or lost to follow-up from this point forward.
Numbers are cumulative. The number of patients in months 6 and 9 boxes total 50 INT and
51 SC if one adds patients deemed eligible1b at preceding visit(s). INT, integrated care
intervention; LTF, lost to follow-up; SC, standard of care; SCID, Structured Clinical
Interview for the DSM-IV.
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Intent-to-treat analysis of treatment eligibility rates. CI, confidence interval; RR, relative
risk.
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Table 1




(n = 50) P value
Age mean (s.e.) 48.3 (0.9) 47.7 (1.1) 0.69
Gender, N (%)
 Male 26 (51) 25 (50) 1.0
 Female 25 (49) 25 (50)
Race, N (%)
 Caucasian 25 (50) 36 (72) 0.04
 Non-Caucasian 26 (50) 14 (28)
Marital status, N (%)
 Married/living w partner 25 (49) 23 (46) 0.32
 Single 15 (29) 10 (20)
 Divorced/separated/widow 11 (22) 17 (34)
Education, N (%)
 < HS graduate 13 (26) 19 (40) 0.33
 HS graduate/GED 15 (30) 12 (26)
 > HS graduate 22 (44) 16 (34)
Income, N (%)
 ≤ 20K per year 37 (82) 39 (83) 1.0
 > 20K per year 8 (18) 8 (17)
Employment status
 Full time/part time 21 (43) 21 (44) 0.08
 Unemployed 17 (35) 7 (15)
 Retired/student/homemaker 3 (6) 6 (12)
 Disabled 8 (16) 14 (29)
Insurance status
 Private insurance 17 (35) 19 (39) 0.93
 Medicare/medicaid 19 (39) 18 (37)
 No insurance/hospital charity care 13 (27) 12 (24)
Reason for deferral
 Alcohol abuse 18 (35) 13 (26) 0.77
 Substance abuse 4 (8) 5 (10)
 Psychiatric disturbance 16 (31) 19 (38)
 Two or more deferral reasons 13 (25) 13 (26)
Genotype
 Genotype 1 38 (74) 39 (78) 0.62
 Genotype 2 or 3 8 (16) 11 (22)
Baseline alcohol mean (s.e.) 9.2 (1.3) 7.5 (1.1) 0.33

















(n = 50) P value
Baseline depression mean (s.e.) 20.0 (2.3) 19.9 (1.9) 0.96
Baseline anxiety mean (s.e.) 38.0 (2.6) 36.3 (1.8) 0.54
Baseline readiness to change mean (s.e.) 9.79 (0.23) 9.03 (0.25) 0.03
GED, general educational development; HS, high school graduate.
Note: Missing data were observed for education and employment (N = 97); income (N = 92); insurance (N = 98); genotype (N = 96); baseline
alcohol, depression, and anxiety (N = 91); and baseline readiness to change (N = 88).
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Table 2
Multivariable logistic regression models
Model Patient characteristic N RR (95% CI) P value
1 Non-Caucasian 101 0.46 (0.20, 1.04) 0.06
2 Income ≤ 20K 92 0.60 (0.34, 1.05) 0.07
3 Genotype 2 or 3 96 1.69 (0.95, 3.00) 0.07
4 Baseline depression 91 0.98 (0.96, 1.00) 0.05
5 Baseline readiness to change 88 0.90 (0.76, 1.06) 0.20
CI, confidence interval; RR, relative risk.
Rows present the results of five separate regression models with each containing treatment condition and the patient characteristic noted. The N for
each model was reduced in some analyses owing to missing data.
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